Ovarian Cancer

When it comes to managing your risk of cancer, especially when dealing with a familial cancer risk, "what is right for one person, may not be right for another," says Amy Byer Shainman.

A second opinion can provide answers, ideas and perspective about whether a patient is on the right treatment path.

On the evolving role of PARP inhibitors in the treatment of ovarian cancer, Donna McNamara, co-chief of Gynecological Oncology at the John Theurer Cancer Center (JTCC), discusses the impact of these studies and the outlook going forward.

There are some things known to increase the risk of gynecologic cancers. Bottom line, being a woman puts you at risk.

The Food and Drug Administration approves Lynparza (olaparib) for the treatment of women with BRCA-positive advanced ovarian cancer.

The FDA approves Avastin in combination with chemotherapy for patients with platinum-resistant recurrent ovarian cancer, based on results of the phase 3 AURELIA trial.

Biomarkers can estimate cancer risk, screen for the disease and confirm a diagnosis.

Patients should research both the surgeon and the technique when deciding on treatment.

The U.S. Supreme Court decides against patents on human genes.

Knowing your risk of a genetic cancer means looking to the past, living in the present and planning for the future.

Reasons for Hope: Options are available to keep disease at bay.

Vaccines help the immune system uncover malignant cells.

To tackle platinum-resistant ovarian cancer, a French research group added Avastin (bevacizumab) to standard chemotherapy.

Avastin appears to reduce relative risk of disease progression in recurring ovarian cancer.

Ovarian cancer survivor, Annette Leal Mattern, offers up advice on living with metastatic disease.

Researchers are looking for effective screening methods for ovarian cancer.

Advances in ovarian cancer gain ground.

The latest in cancer prevention, diagnosis & treatment

PARP inhibitors continue to look “promising.”

For those weighing whether to get their BRCA mutation status checked, the potential promise of the PARP inhibitors shouldn’t tip the balance—yet.

Researchers have developed a new screening approach that produces very few false positives in postmenopausal women with an average risk of ovarian cancer.

Continued use of the targeted drug Avastin (bevacizumab), after initial treatment with the drug and chemotherapy, helped slow progression of advanced ovarian cancer, according to a phase 3 study.

Updates from the annual meeting of the American Society of Clinical Oncology.

Treating an ovarian cancer relapse as soon as it can be detected seems like a good idea. But not so fast, a major study has concluded.

Ovarian cancer survivors ponder implications of CA-125 study.

News from the 2009 annual meeting of the American Society of Clinical Oncology.

Results from an international study challenge current practice of screening for ovarian cancer relapse.

Controlling lymphedema with the old and the new.

Ovarian cancer, also known as “the silent killer,” may soon be detected earlier, giving women improved survival rates, with the recognition of specific early warning signs which including abdominal pain, abdominal bloating, urinary urgency or frequency, pelvic and lower back pressure, loss of appetite or feeling full quickly and abnormal vaginal bleeding.

Paying attention to early symptoms of ovarian cancer may give a voice to the "silent killer," but some advise caution.